Brief: BenevolentAi Announces Top-Line Phase IIA Results For Atopic Dermatitis Inhibitor

BenevolentAI SA

05/04/2023 06:13

April 5 (Reuters) - BenevolentAI SA  BAI.AS :
    * BENEVOLENTAI ANNOUNCES TOP-LINE PHASE IIA RESULTS FOR ITS
TOPICAL PAN-TRK INHIBITOR BEN-2293 (1%) IN MILD-TO-MODERATE
ATOPIC DERMATITIS
    * SUCCESSFULLY MET PRIMARY ENDPOINT WITH BEN-2293 FOUND TO
BE SAFE
AND WELL TOLERATED
    * COMPANY IS CONDUCTING A REVIEW OF FULL DATASET TO HELP
GUIDE
FURTHER DEVELOPMENT FOR BEN-2293 AND IT WILL REPORT FULL RESULTS
AT A LATER DATE, AS WARRANTED

Source text for Eikon:  ID:nBw6WLj1Qa 
Further company coverage:  BAI.AS 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;))